Connect with us

Life Sciences

Fraunhofer IZI Selects Lonza’s MODA-ES Solution to Digitalize Manufacturing Operations

Fraunhofer IZI, one of Europe’s leading manufacturers of cell and gene therapies for clinical trials, intends to digitalize its manufacturing operations…

Published

on

This article was originally published by AITHORITY
Fraunhofer IZI Selects Lonza’s MODA-ES Solution to Digitalize Manufacturing Operations

Fraunhofer IZI, one of Europe’s leading manufacturers of cell and gene therapies for clinical trials, intends to digitalize its manufacturing operations with MODA-ES, the Manufacturing Execution System from Lonza. Fraunhofer IZI will use Lonza’s MODA-ES to facilitate its transition from an entirely paper-based, manual documentation process to an automated, fully electronic GMP-compliant system.

Latest NaturalAI Insights: InspireXT Announces Acquisition Of NaturalAI – A Conversational Artificial Intelligence Platform To Expand Its Solution Portfolio

Manufacturing cell and gene therapies — advanced therapy medicinal products — requires extensive documentation of all manufacturing and verification steps to ensure patient safety and GMP compliance. For organizations with such complex workflows, selecting the right electronic batch record solution is critical.

Dr. Gerno Schmiedeknecht, Head of the Department GMP Cell and Gene Therapy, Fraunhofer IZI, commented: “With the introduction of fully electronic batch documentation, manufacturing and batch release for our customers and partners will be even safer, faster, more cost-effective and generally more efficient. In addition, this measure leads to higher flexibility in a pandemic situation, as the process of reviewing the batch documentation and the batch release, in particular, can largely be carried out in remote mode without direct onsite presence.”

AI News: Darth Vader, Cyber Cartography and the Future of Creativity—Powered by AI

David McErlane, SVP, Head of Bioscience, Lonza, added: “We are excited to support Fraunhofer IZI with their MODA-ES® Implementation. Electronic batch records have been unattainable to most of the industry due to cost constraints and flexibility concerns. With a deep understanding of the challenges faced by cell and gene manufacturers, we designed MODA-ES® with the end user in mind to provide a cost-effective and usable solution that meets each of our customers’ requirements.”

The MODA® Platform bridges the gap between manufacturing and quality control, providing a mechanism to produce a single electronic batch record. Lonza’s manufacturing and lab execution software enables data capture and provides workflow and analytical tools to expedite product release. With a focus on a user-centric, scalable solution that may be implemented in an accelerated timeline, the MODA® Platform supports customers in their efforts to realize their digitalization goals.

The Natural Language Processing Techniques : The Electronic Medical Records Market Sees A Rising Adoption Of The Natural Language Processing Techniques By The Business Research Company

 [To share your insights with us, please write to sghosh@martechseries.com] 

The post Fraunhofer IZI Selects Lonza’s MODA-ES Solution to Digitalize Manufacturing Operations appeared first on AiThority.


gene therapy

artificial intelligence

Life Sciences

Wittiest stocks:: Avalo Therapeutics Inc (NASDAQ:AVTX 0.00%), Nokia Corp ADR (NYSE:NOK 0.90%)

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…

Continue Reading
Life Sciences

Spellbinding stocks: LumiraDx Limited (NASDAQ:LMDX 4.62%), Transocean Ltd (NYSE:RIG -2.67%)

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…

Continue Reading
Life Sciences

Asian Fund for Cancer Research announces Degron Therapeutics as the 2023 BRACE Award Venture Competition Winner

The Asian Fund for Cancer Research (AFCR) is pleased to announce that Degron Therapeutics was selected as the winner of the 2023 BRACE Award Venture Competition….

Continue Reading

Trending